Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213077 | 1.00 | PPARG (0.46) | PPARGCYP1A1CYP1B1HDAC8POLB | |
| SCHEMBL3901322 | 0.86 | MAPT (0.55) | CYP1A1CYP1B1MEN1KMT2AALDH1A1 | |
| SCHEMBL3902810 | 0.86 | MAPT (0.55) | CYP1A1CYP1B1MEN1KMT2AALDH1A1 | |
| SCHEMBL13168891 | 0.79 | MAPT (0.61) | CYP1A1CYP1B1HDAC8MEN1KMT2A | |
| SCHEMBL8420226 | 0.78 | TUBB1 (0.41) | PPARGKMT2AALDH1A1MAPT | |
| SCHEMBL18538454 | 0.78 | CYP1A1 (0.50) | CYP1A1CYP1B1HDAC8ALDH1A1MAPT | |
| SCHEMBL3208404 | 0.77 | HDAC8 (0.64) | HDAC8ALDH1A1MAPTPLA2G2D | |
| SCHEMBL3204781 | 0.77 | GAA (0.49) | PPARGCYP1A1CYP1B1HDAC8POLB | |
| SCHEMBL3204757 | 0.77 | GAA (0.49) | PPARGCYP1A1CYP1B1HDAC8POLB | |
| SCHEMBL3208391 | 0.77 | HDAC8 (0.64) | HDAC8ALDH1A1MAPTPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885CYP1A1 2809/4885CYP1B1 2548/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885CYP1A1 2059/4885CYP1B1 2202/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885CYP1A1 2809/4885CYP1B1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.